loader
Please Wait
Applying Filters...
menu
    • menu

    Quality Alerts: FDA Issues Form 483 to Granules - Granules India Limited

    MenuGranules India Limited

    Uploaded: 2022
    News
    Granules India Q4FY26 revenue jumps 23% to Rs 14,706 million

    29 Apr 2026

    // INDPHARMAPOST

    Granules Life receives VAI Classification for Shamirpet facility

    01 Apr 2026

    // PRESS RELEASE

    Granules India’s US packaging facility Passes FDA Inspection

    06 Mar 2026

    // PRESS RELEASE

    DATA COMPILATION
    #PharmaFlow

    Granules India

    Contact Supplier

    Website

    CPhI China

    Booth #E1K58

    Book a meeting

    envelop Contact Supplier

    Latest Content by PharmaCompass

    https://www.pharmacompass.com/video-pharmareel/granules-india-limited/an-illustrious-journey-of-more-than-4-decades
    Xls

    CATEGORY PAGE
    Menu

    Granules India Limited

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    Key Products KEY PRODUCTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    PC100397
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.